葛兰素史克GSK-201507-Q2-2015-Analyst-slide-presentation.pdf

1、Q2 2015 results 29 July 2015 Cautionary statement regarding forward-looking statements 2 This presentation may contain forward-looking statements.Forward-looking statements give the Groups current expectations or forecasts of future events.An investor can identify these statements by the fact that t

2、hey do not relate strictly to historical or current facts.They use words such as anticipate,estimate,expect,intend,will,project,plan,believe,target and other words and terms of similar meaning in connection with any discussion of future operating or financial performance.In particular,these include

3、statements relating to future actions,prospective products or product approvals,future performance or results of current and anticipated products,sales efforts,expenses,the outcome of contingencies such as legal proceedings,and financial results.Other than in accordance with its legal or regulatory

4、obligations(including under the UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority),the Group undertakes no obligation to update any forward-looking statements,whether as a result of new information,future events or otherwise.Investors should,however,consul

5、t any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission(SEC).All investors,wherever located,should take note of these disclosures.Accordingly,no assurance can be given that any particular expectation will be

6、 met and investors are cautioned not to place undue reliance on the forward-looking statements.Forward-looking statements are subject to assumptions,inherent risks and uncertainties,many of which relate to factors that are beyond the Groups control or precise estimate.The Group cautions investors th

7、at a number of important factors,including those in this document,could cause actual results to differ materially from those expressed or implied in any forward-looking statement.Such factors include,but are not limited to,those discussed under Item 3.D Risk factors in the Groups Annual Report on Fo

8、rm 20-F for 2014 and those discussed in Part 2 of the Circular to Shareholders and Notice of General Meeting furnished to the SEC on Form 6-K on November 24,2014.Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge

9、and information available to the Directors on the date of this report.A number of adjusted measures are used to report the performance of our business.These measures are defined in our Q2 2015 earnings release and annual report on Form 20-F.Balanced business,driven by new products and R&D innovation

10、 3*2014 sales restated to exclude Oncology and include 12 months of NVS sales.Three world leading businesses*Positively exposed in more than 150 markets to broad areas of healthcare demand and growth with new product growth Rx:Tivicay and Triumeq continue to beat expectations Vx:Newly acquired Menin

11、gitis vaccines Bexsero and Menveo Cx:Flonase OTC launch 294m 73m 45m Q2 highlights Q2 sales and significant further potential from the pipeline c.40 NMEs(drugs and vaccines)in Phase II/III clinical development,primarily focussed on HIV,Oncology,Vaccines,Cardiovascular,Immuno-Inflammation and Respira

12、tory diseases Rx 59%Vx 16%Cx 25%Sustained delivery of innovation in 2015 4 FDA decision on Nucala for severe eosinophilic asthma 4th Nov Readout of Breo SUMMIT study of mortality and morbidity in COPD Part A of Phase III study for losmapimod for ACS Phase III data for sirukumab for RA R&D Event 3rd

13、Nov will review data and prospects for advanced/early stage pipeline H2 milestones include FDA approval for Breo asthma Strimvelis gene therapy filed in Europe for ADA SCID Nucala received FDA AdCom recommendation and regulatory filing for approval in Japan Positive CHMP decision received for Mosqui

14、rix H1 regulatory progress includes Earnings and returns to shareholders 5 2015 Q2 dividend 19p per share declared and delivery of returns to shareholders*All growth rates CER.2015 growth is compared to 95.4p core reported 2014 EPS.All expectations and targets regarding future performance should be

15、read together with the“Cautionary statement regarding forward-looking statements”section of the Q2 Results Announcement 2015 Core EPS Expected decline of high teens%*2016 Core EPS Expected to reach double digit%growth*2015 earnings guidance and 2016 outlook reiterated at second quarter 2015-2017 Div

16、idends Plan to pay annual ordinary dividend of 80p per share Core results Q2 2015 Q2 Growth H1 2015 H1 Growth m m CER%m CER%Turnover 5,888 7 6 11,510 4 3 Core operating profit 1,349 3(4)2,654(6)(10)Core EPS 17.3p-(9)34.6p(8)(14)Headline results from Q2 and H1 6 Total results Q2 2015 Q2 Growth H1 2015 H1 Growth m m CER%m CER%Turnover 5,888 7 6 11,510 4 3 Operating profit 335(61)(71)9,551 100 100 EPS 3.1p(63)(77)170.7p 100 100 Q2 2015 sales and core operating profit margin 7 5.8bn6.0bn5.9bn+2%+6%-